Editor-in-Chief: Prof. Christoph Plass
Journal list menu
Journal Overview
The International Journal of Cancer (IJC) is the official journal of the Union for International Cancer Control (UICC). IJC has a global readership and receives over 3,000 submissions a year under a broad scope of topics relevant to experimental and clinical cancer research. We invite and encourage original Research Articles and Short Reports.
Editor's Choice: October (Issue 8)
Ionizing radiation promotes, whereas calorie restriction suppresses, NASH and hepatocellular carcinoma in mice
Yi Shang et al.
Read previous Editor's Choices
Editor's Choice: October (Issue 7)
Cancer incidence among Chernobyl cleanup workers from Estonia: A 34-year follow-up
Kaja Rahu et al.
Read previous Editor's Choices
Editor's Choice: September (Issue 6)
Editor's Choice: September (Issue 5)
Genetic deletion or tyrosine phosphatase inhibition of PTPRZ1 activates c-Met to up-regulate angiogenesis and lung adenocarcinoma growth
Pinelopi Kastana et al.
Read previous Editor's Choices
Articles
Maternal medically diagnosed infection and antibiotic prescription during pregnancy and risk of childhood cancer: A population‐based cohort study in Taiwan, 2004 to 2015
- 4 October 2023
What's new?
What's new?
Maternal infection and antibiotic exposure during pregnancy are potential risk factors for childhood cancer. Previous studies of possible associations between these factors and childhood cancer risk, however, have focused mainly on European and U.S. populations. Here, relationships between childhood cancer and medically diagnosed maternal infection and antibiotic use during pregnancy were explored in a Taiwanese population. Analyses reveal moderate associations between maternal infection during pregnancy and childhood hepatoblastoma risk and risk of childhood acute lymphoblastic leukemia (ALL). Maternal use of certain antibiotics during pregnancy increased childhood hepatoblastoma and ALL risk, with ALL risk especially linked to maternal tetracycline use.
Cost‐effectiveness of risk‐based low‐dose computed tomography screening for lung cancer in Switzerland
- 4 October 2023
What's new?
What's new?
Throughout Europe, computed tomography screening for lung cancer is in a phase of clinical implementation or reimbursement evaluation. Efficient selection of individuals for screening is however essential. This microsimulation-based cost-effectiveness analysis offers the first comparative evidence for risk-based and pack-year-based lung cancer screening with low-dose computed tomography in a European country. Risk-based screening using a 1.6% PLCOm2012 eligibility threshold achieves a higher mortality reduction (11.0% vs 10.5%) than screening individuals with 20 pack-years, at a 7.3% lower cost per quality-adjusted life year gained. Policy makers should consider the increased selection efficiency of risk prediction models when implementing population screening programmes.
Current status and challenges of gastrointestinal cancer treatment in China
- 1875-1876
- 3 October 2023
Immune landscape of vulvar cancer patients treated with surgery and adjuvant radiotherapy revealed restricted T cell functionality and increased IL‐17 expression associated with cancer relapse
- 3 October 2023
What's new?
What's new?
Vulvar cancer is a rare gynecologic tumor treated with radiotherapy that affects the host immune system. Here, we provide new insight into systemic therapy-induced individual immunity of patients, revealing increased frequencies of tumor-promoting interleukin(IL)-17-producing CD4+ and CD8+ T cell subsets after radiotherapy, while other T cell subsets important for cancer cell elimination, like T-helper (Th)1 and cytotoxic T cells, were decreased and showed high expression of the Programmed Cell Death Protein (PD) 1 indicating restricted functionality. Moreover, this imbalance within the post-therapeutic immune milieu was associated with shorter recurrence free survival suggesting IL-17 and PD-1 as target for immunotherapy in vulvar cancers.
The following is a list of the most accessed articles in 2018.
Cancer statistics for the year 2020: An overview
- 778-789
- 5 April 2021
Abstract
What's new?
As part of the latest International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics update, here the authors provide a comprehensive description of the data sources and methods used to compute the global incidence and mortality estimates for 38 cancers corresponding to the year 2020. The reported uncertainty intervals incorporate the major sources of error that may contribute to the uncertainty of these estimations. In addition to providing a global snapshot of the cancer burden in 2020, the estimates presented here can support the planning and prioritization of cancer control efforts at the global and national levels.
Tobacco smoking and cancer: A meta‐analysis
- 155-164
- 26 October 2007
A brief history of cancer: Age‐old milestones underlying our current knowledge database
- 2022-2036
- 11 August 2014
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- E359-E386
- 13 September 2014
Abstract
What's new?
In this report, we present the most recent cancer incidence and mortality statistics (for 2012) for the major cancers in 20 regions of the world. Details of the data sources and methods used in GLOBOCAN to compile the estimates at the national level are provided, and we introduce a novel alphanumeric scoring system to give a broad indication of the robustness of the estimation within each country. A global snapshot of the patterns by cancer site brings focus to the need for regional prioritisation of cancer control efforts, as well as the ongoing efforts to improve the limited surveillance systems in many low and middle income countries.
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- 1941-1953
- 23 October 2018
Abstract
What's new?
The GLOBOCAN database, compiled by the International Agency for Research on Cancer (IARC), is updated regularly, providing timely estimates on national cancer incidence and mortality. Here, the authors, associated with the IARC, describe the data sources and methods used to compute global cancer incidence and mortality estimates for 38 specific cancers detailed in GLOBOCAN 2018. The authors further describe novel uncertainty intervals, newly derived from a method incorporating covariates that contribute to uncertainty in cancer estimation. Uncertainty intervals are presented alongside overall estimates, which indicate that 18.1 million new cancer cases and 9.6 million cancer deaths occurred globally in 2018.
The following is a list of the most cited articles based on citations published in the last three years, according to CrossRef.
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- International Journal of Cancer
- E359-E386
- 13 September 2014
Abstract
What's new?
In this report, we present the most recent cancer incidence and mortality statistics (for 2012) for the major cancers in 20 regions of the world. Details of the data sources and methods used in GLOBOCAN to compile the estimates at the national level are provided, and we introduce a novel alphanumeric scoring system to give a broad indication of the robustness of the estimation within each country. A global snapshot of the patterns by cancer site brings focus to the need for regional prioritisation of cancer control efforts, as well as the ongoing efforts to improve the limited surveillance systems in many low and middle income countries.
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- International Journal of Cancer
- 1941-1953
- 23 October 2018
Abstract
What's new?
The GLOBOCAN database, compiled by the International Agency for Research on Cancer (IARC), is updated regularly, providing timely estimates on national cancer incidence and mortality. Here, the authors, associated with the IARC, describe the data sources and methods used to compute global cancer incidence and mortality estimates for 38 specific cancers detailed in GLOBOCAN 2018. The authors further describe novel uncertainty intervals, newly derived from a method incorporating covariates that contribute to uncertainty in cancer estimation. Uncertainty intervals are presented alongside overall estimates, which indicate that 18.1 million new cancer cases and 9.6 million cancer deaths occurred globally in 2018.
Cancer statistics for the year 2020: An overview
- International Journal of Cancer
- 778-789
- 5 April 2021
Abstract
What's new?
As part of the latest International Agency for Research on Cancer (IARC) GLOBOCAN cancer statistics update, here the authors provide a comprehensive description of the data sources and methods used to compute the global incidence and mortality estimates for 38 cancers corresponding to the year 2020. The reported uncertainty intervals incorporate the major sources of error that may contribute to the uncertainty of these estimations. In addition to providing a global snapshot of the cancer burden in 2020, the estimates presented here can support the planning and prioritization of cancer control efforts at the global and national levels.
Recent issues
IssueVolume 153, Issue 11Current status and challenges of gastrointestinal cancer treatment in China
1871-19291 December 2023Lin Shen
Latest news
Sign up for email alerts
Tools
Published on behalf of the Union for International Cancer Control (UICC)
More from this journal
Download the Journal App
